RAP1GAP2

Summary

RAP1GAP2 (RAP1 GTPase activating protein 2, HGNC:29176) is a protein-coding gene on chromosome 17p13.3, encoding Rap1 GTPase-activating protein 2 (Q684P5). GTPase activator for the nuclear Ras-related regulatory protein RAP-1A (KREV-1), converting it to the putatively inactive GDP-bound state.

This gene encodes a GTPase-activating protein that activates the small guanine-nucleotide-binding protein Rap1 in platelets. The protein interacts with synaptotagmin-like protein 1 and Rab27 and regulates secretion of dense granules from platelets at sites of endothelial damage. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 23108 — RefSeq curated summary.

At a glance

• GWAS associations: 26
• Clinical variants (ClinVar): 121 total — 2 pathogenic
• MANE Select transcript: NM_015085

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29176
Approved symbol	RAP1GAP2
Name	RAP1 GTPase activating protein 2
Location	17p13.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1039
Ensembl gene	ENSG00000132359
Ensembl biotype	protein_coding
OMIM	618714
Entrez	23108

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000254695, ENST00000366401, ENST00000540393, ENST00000571555, ENST00000574515, ENST00000574709, ENST00000575979, ENST00000637138, ENST00000697391, ENST00000697392, ENST00000905763

RefSeq mRNA: 5 — MANE Select: NM_015085 NM_001100398, NM_001330058, NM_001411048, NM_001411049, NM_015085

CCDS: CCDS45573, CCDS45574, CCDS82035, CCDS92223, CCDS92224

Canonical transcript exons

ENST00000254695 — 25 exons

Exon	Start	End
ENSE00000430869	3008011	3008145
ENSE00000668753	3005369	3005440
ENSE00001116175	3030922	3030998
ENSE00001116182	3026008	3026121
ENSE00001116183	3026944	3027070
ENSE00001116184	3026350	3026464
ENSE00001292032	2991297	2991397
ENSE00001400229	2981195	2981248
ENSE00001403726	2980287	2980365
ENSE00001404136	2905284	2905368
ENSE00001407242	2957759	2957794
ENSE00001418108	2965540	2965643
ENSE00001422981	2963856	2964068
ENSE00001426303	2984983	2985066
ENSE00001427626	2963430	2963462
ENSE00001431800	2962670	2962714
ENSE00001613212	3032411	3032449
ENSE00002634319	2796438	2796571
ENSE00003552310	2998221	2998376
ENSE00003559717	3018061	3018198
ENSE00003565722	3020477	3020595
ENSE00003602318	2800515	2800550
ENSE00003664553	3005955	3006041
ENSE00003679172	2995337	2995466
ENSE00003850158	3033392	3037741

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 97.33.

FANTOM5 (CAGE): breadth broad, TPM avg 5.3941 / max 535.4932, expressed in 518 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158858	4.4929	373
158857	0.3151	109
158852	0.3085	144
158855	0.1328	60
158856	0.0613	38
208029	0.0527	26
158854	0.0172	8
158853	0.0136	4

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	97.33	gold quality
middle temporal gyrus	UBERON:0002771	95.38	silver quality
endothelial cell	CL:0000115	95.24	silver quality
superior frontal gyrus	UBERON:0002661	94.73	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.70	gold quality
cerebellum	UBERON:0002037	94.54	gold quality
cerebellar hemisphere	UBERON:0002245	94.52	gold quality
cerebellar cortex	UBERON:0002129	94.50	gold quality
islet of Langerhans	UBERON:0000006	94.43	gold quality
postcentral gyrus	UBERON:0002581	94.26	gold quality
cerebellar vermis	UBERON:0004720	94.01	gold quality
entorhinal cortex	UBERON:0002728	93.92	gold quality
type B pancreatic cell	CL:0000169	93.86	silver quality
granulocyte	CL:0000094	93.76	gold quality
primary visual cortex	UBERON:0002436	93.66	gold quality
parietal lobe	UBERON:0001872	93.61	gold quality
occipital lobe	UBERON:0002021	92.76	gold quality
blood	UBERON:0000178	92.29	gold quality
frontal cortex	UBERON:0001870	92.20	gold quality
pancreas	UBERON:0001264	92.19	gold quality
right frontal lobe	UBERON:0002810	92.04	gold quality
pancreatic ductal cell	CL:0002079	91.83	silver quality
body of pancreas	UBERON:0001150	91.72	gold quality
body of stomach	UBERON:0001161	91.53	gold quality
neocortex	UBERON:0001950	91.53	gold quality
orbitofrontal cortex	UBERON:0004167	91.46	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	91.41	gold quality
prefrontal cortex	UBERON:0000451	91.21	gold quality
cingulate cortex	UBERON:0003027	90.88	gold quality
anterior cingulate cortex	UBERON:0009835	90.80	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	61.14
E-ANND-3	yes	6.14
E-MTAB-8060	no	65.70

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

187 targeting RAP1GAP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-3658	99.96	73.87	4379
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4492	99.87	68.25	3611
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-4728-5P	99.85	69.39	4718

Literature-anchored findings (GeneRIF, showing 3)

• Rap1GAP2 is the first GTPase-activating protein of Rap1 found in platelets and is likely to have an important regulatory role in platelet aggregation (PMID:15632203)
• Platelet activation by ADP and thrombin enhances serine 9 phosphorylation and increases 14-3-3 binding to endogenous Rap1GAP2. (PMID:18039662)
• Slp1 inhibits dense granule secretion in platelets and that Rap1GAP2 modulates secretion by binding to Slp1. (PMID:19528539)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	rap1gap2a	ENSDARG00000061551
danio_rerio	rap1gap2b	ENSDARG00000074222
danio_rerio	rap1gapl	ENSDARG00000091573
mus_musculus	Rap1gap2	ENSMUSG00000038807
rattus_norvegicus	Rap1gap2	ENSRNOG00000002652
drosophila_melanogaster	RapGAP1	FBGN0264895
caenorhabditis_elegans		WBGENE00018734

Paralogs (6): RAP1GAP (ENSG00000076864), SIPA1L3 (ENSG00000105738), SIPA1L2 (ENSG00000116991), GARNL3 (ENSG00000136895), SIPA1L1 (ENSG00000197555), SIPA1 (ENSG00000213445)

Protein

Protein identifiers

Rap1 GTPase-activating protein 2 — Q684P5 (reviewed: Q684P5)

Alternative names: GTPase-activating Rap/Ran-GAP domain-like protein 4

All UniProt accessions (4): Q684P5, A0A1B0GV05, A0A8V8TKZ8, A0A8V8TL16

UniProt curated annotations — full annotation on UniProt →

Function. GTPase activator for the nuclear Ras-related regulatory protein RAP-1A (KREV-1), converting it to the putatively inactive GDP-bound state.

Subcellular location. Cytoplasm. Perinuclear region.

Tissue specificity. Isoform 1 and isoform 2 are expressed in platelets with isoform 2 being the predominant form. Expressed in lymphocytes, heart, testis and pancreas.

Post-translational modifications. In vitro phosphorylated by cGMP-dependent protein kinase 1 (cGKI) at Ser-7; the phosphorylation probably does not regulate GAP activity.

Isoforms (3)

UniProt ID	Names	Canonical?
Q684P5-1	1, Rap1GAP2b	yes
Q684P5-2	2, Rap1GAP2a
Q684P5-3	3, Rap1GAP2c

RefSeq proteins (5): NP_001093868, NP_001316987, NP_001397977, NP_001397978, NP_055900* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000331	Rap/Ran_GAP_dom	Domain
IPR035974	Rap/Ran-GAP_sf	Homologous_superfamily
IPR050989	Rap1_Ran_GAP	Family

Pfam: PF02145, PF21022

UniProt features (28 total): modified residue 9, compositionally biased region 6, region of interest 3, sequence conflict 3, splice variant 2, mutagenesis site 2, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q684P5-F1	66.02	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 7, 45, 49, 507, 544, 558, 564, 612, 613

Mutagenesis-validated functional residues (2):

Position	Phenotype
7	abolishes phosphorylation by pkg/prkg1.
357	abolishes gap activity.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-392517	Rap1 signalling
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 288 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_DN, AP1_01, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, CHUNG_BLISTER_CYTOTOXICITY_DN, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, TGACCTY_ERR1_Q2, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_SIZE, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, GOCC_CENTROSOME, GOBP_REGULATION_OF_CELL_SIZE, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, GOBP_ADAPTIVE_IMMUNE_RESPONSE, KIM_GERMINAL_CENTER_T_HELPER_DN, GOCC_NEURON_PROJECTION

GO Biological Process (3): adaptive immune response (GO:0002250), regulation of cell size (GO:0008361), regulation of small GTPase mediated signal transduction (GO:0051056)

GO Molecular Function (2): GTPase activator activity (GO:0005096), protein binding (GO:0005515)

GO Cellular Component (9): cytoplasm (GO:0005737), centrosome (GO:0005813), centriole (GO:0005814), cytosol (GO:0005829), plasma membrane (GO:0005886), nuclear membrane (GO:0031965), perinuclear theca (GO:0033011), sperm principal piece (GO:0097228), perinuclear region of cytoplasm (GO:0048471)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Adaptive Immune System	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
microtubule organizing center	2
cytoplasm	2
immune response	1
regulation of cellular component size	1
small GTPase-mediated signal transduction	1
regulation of intracellular signal transduction	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
binding	1
intracellular anatomical structure	1
centriole	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
nucleus	1
nuclear envelope	1
organelle membrane	1
cytoskeleton	1
perinuclear region of cytoplasm	1
sperm flagellum	1

Protein interactions and networks

STRING

658 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAP1GAP2	RNF6	Q9Y252	411
RAP1GAP2	RASGRP2	Q7LDG7	401
RAP1GAP2	RASA3	Q14644	377
RAP1GAP2	RYK	P34925	372
RAP1GAP2	RAP1B	P09526	345
RAP1GAP2	BEX5	Q5H9J7	336
RAP1GAP2	SBK1	Q52WX2	310
RAP1GAP2	PLPP2	O43688	306
RAP1GAP2	ZNF251	Q9BRH9	297
RAP1GAP2	DIRAS2	Q96HU8	296
RAP1GAP2	ANKRD18B	A2A2Z9	295
RAP1GAP2	RAP1A	P10113	295
RAP1GAP2	RAPGEF1	Q13905	294
RAP1GAP2	RAP1GDS1	P52306	290
RAP1GAP2	LRPAP1	P30533	289

IntAct

11 interactions, top by confidence:

A	B	Type	Score
RAP1GAP2	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
RAP1GAP	RAP1GAP2	psi-mi:“MI:0915”(physical association)	0.500
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
RAP1GAP	VPS26A	psi-mi:“MI:0914”(association)	0.350
PIP4K2A	SAP18	psi-mi:“MI:0914”(association)	0.350
RAP1GAP2	MEOX2	psi-mi:“MI:0915”(physical association)	0.000
RAP1GAP2	YWHAE	psi-mi:“MI:0915”(physical association)	0.000
WNK1	RAP1GAP2	psi-mi:“MI:0915”(physical association)	0.000
VPS26C	RAP1GAP2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (34): RAP1GAP2 (Affinity Capture-MS), RAP1GAP2 (Affinity Capture-RNA), RAP1GAP2 (Two-hybrid), RAP1GAP2 (Affinity Capture-MS), RAP1GAP2 (Affinity Capture-MS), RAP1GAP2 (Affinity Capture-RNA), RAP1GAP2 (Two-hybrid), RAP1GAP2 (Affinity Capture-MS), RAP1GAP2 (Affinity Capture-RNA), RAP1GAP2 (Proximity Label-MS), RAP1GAP2 (Proximity Label-MS), RAP1GAP2 (Proximity Label-MS), RAP1GAP2 (Proximity Label-MS), RAP1GAP2 (Proximity Label-MS), RAP1GAP2 (Proximity Label-MS)

ESM2 similar proteins: A1Z7A6, A2ALS5, A5PF44, A7KAX9, A8E7C5, A8JQ65, B3LXF2, B3NYS4, B4I4Y1, B4JHJ7, B4K6T8, B4PRE2, B4R0A5, G3X9J0, G5EFI8, O35412, O35711, O43166, O60292, P43125, P47736, Q14693, Q22744, Q2NKQ1, Q2PE14, Q3V0G7, Q4P3S3, Q5JCS6, Q5SVL6, Q5VVW2, Q5ZJY3, Q5ZMV8, Q684P5, Q80TE4, Q811P8, Q8BPQ7, Q8C0T5, Q8C8U0, Q8CDA1, Q91ZP3

Diamond homologs: A2ALS5, A5PF44, G3X9J0, O35412, O43166, O60292, P46062, P47736, P49815, P49816, Q3V0G7, Q54EH3, Q55AN8, Q5JCS6, Q5SVL6, Q5VVW2, Q5ZJY3, Q5ZMV8, Q61037, Q684P5, Q75J96, Q80TE4, Q8C0T5, Q96FS4, Q9P2F8, Q2PPJ7, Q9UUG9, A3KGS3, P86411, Q6GYQ0, Q8BUL6, Q9HB21, Q54TK4, Q9VB98, O55007, Q6GYP7, Q54SS8, P86409

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

121 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	77
Likely benign	6
Benign	3

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
815888	GRCh37/hg19 17p13.3(chr17:2325226-2808483)x1	Pathogenic
815889	GRCh37/hg19 17p13.3(chr17:2416838-2784745)x1	Pathogenic

SpliceAI

6346 predictions. Top by Δscore:

Variant	Effect	Δscore
17:2796539:G:GT	donor_gain	1.0000
17:2800546:GTCAA:G	donor_gain	1.0000
17:2800551:G:GG	donor_gain	1.0000
17:2905365:GAAG:G	donor_gain	1.0000
17:2905367:AGGT:A	donor_loss	1.0000
17:2905368:GGT:G	donor_loss	1.0000
17:2905370:T:G	donor_loss	1.0000
17:2963463:GTAG:G	donor_loss	1.0000
17:2964066:AAG:A	donor_loss	1.0000
17:2964067:AGGT:A	donor_loss	1.0000
17:2964069:G:GA	donor_loss	1.0000
17:2964070:T:A	donor_loss	1.0000
17:2980275:C:CA	acceptor_gain	1.0000
17:2980283:GCA:G	acceptor_loss	1.0000
17:2980284:CAGGT:C	acceptor_loss	1.0000
17:2980285:A:AC	acceptor_loss	1.0000
17:2980285:A:AG	acceptor_gain	1.0000
17:2980286:G:GG	acceptor_gain	1.0000
17:2980286:GGTCC:G	acceptor_gain	1.0000
17:2981247:AGGTA:A	donor_loss	1.0000
17:2981248:GGTAA:G	donor_loss	1.0000
17:2981249:GTA:G	donor_loss	1.0000
17:2981250:T:A	donor_loss	1.0000
17:2991291:TTTCA:T	acceptor_loss	1.0000
17:2991292:TTCAG:T	acceptor_loss	1.0000
17:2991293:TCAG:T	acceptor_loss	1.0000
17:2991294:CAG:C	acceptor_loss	1.0000
17:2991295:A:AG	acceptor_gain	1.0000
17:2991295:A:C	acceptor_loss	1.0000
17:2991296:G:GA	acceptor_gain	1.0000

AlphaMissense

4834 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:2964058:T:C	F161S	1.000
17:2965643:G:C	R199T	1.000
17:2965643:G:T	R199M	1.000
17:2985034:A:G	K261E	1.000
17:2985035:A:T	K261I	1.000
17:2985036:A:C	K261N	1.000
17:2985036:A:T	K261N	1.000
17:2985041:G:A	G263E	1.000
17:2985044:T:A	V264D	1.000
17:2991366:G:T	G295W	1.000
17:2991367:G:A	G295E	1.000
17:2991390:T:C	F303L	1.000
17:2991392:C:A	F303L	1.000
17:2991392:C:G	F303L	1.000
17:2995338:T:C	F306L	1.000
17:2995340:C:A	F306L	1.000
17:2995340:C:G	F306L	1.000
17:2995345:G:A	G308E	1.000
17:2995351:T:A	L310Q	1.000
17:2995351:T:C	L310P	1.000
17:2995374:G:T	G318W	1.000
17:2995375:G:A	G318E	1.000
17:2995383:T:C	S321P	1.000
17:2995420:T:C	F333S	1.000
17:2995422:C:G	H334D	1.000
17:2995426:T:A	V335D	1.000
17:2995438:T:C	L339P	1.000
17:2998228:G:C	R351T	1.000
17:2998229:A:C	R351S	1.000
17:2998229:A:T	R351S	1.000

dbSNP variants (sampled 300 via entrez): RS1000004387 (17:2875712 G>A), RS1000012902 (17:2966091 A>T), RS1000042148 (17:2920369 G>A), RS1000046494 (17:3023108 T>A), RS1000047982 (17:2805061 T>C), RS1000067986 (17:2813302 C>T), RS1000084790 (17:2850031 C>A,T), RS1000092474 (17:2769675 G>T), RS1000093430 (17:2845638 G>A), RS1000102497 (17:3013731 C>T), RS1000112352 (17:2916607 G>A,T), RS1000124841 (17:2773747 A>G), RS1000127574 (17:2784653 C>G,T), RS1000128566 (17:3016933 G>A), RS1000144219 (17:2784102 A>G)

Disease associations

OMIM: gene MIM:618714 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

26 associations (top):

Study	Trait	p-value
GCST001099_10	Sudden cardiac arrest	3.000000e-06
GCST002279_97	PR interval in Tripanosoma cruzi seropositivity	6.000000e-07
GCST002445_6	Asthma (sex interaction)	3.000000e-07
GCST002740_26	Inflammatory skin disease	9.000000e-06
GCST003995_24	Tonsillectomy	2.000000e-09
GCST004627_164	Lymphocyte count	2.000000e-17
GCST004627_165	Lymphocyte count	8.000000e-14
GCST005014_191	Tonsillectomy	2.000000e-09
GCST008758_71	Pre-treatment viral load in HIV-1 infection	6.000000e-17
GCST009313_2	Prepulse inhibition of the startle response	8.000000e-07
GCST012020_158	Serum metabolite levels	7.000000e-11
GCST012021_83	Serum metabolite levels	7.000000e-11
GCST012490_481	Femur bone mineral density x serum urate levels interaction	1.000000e-09
GCST90002379_180	Basophil count	8.000000e-10
GCST90002381_103	Eosinophil count	5.000000e-09
GCST90002381_104	Eosinophil count	1.000000e-10
GCST90002388_479	Lymphocyte count	3.000000e-31
GCST90002388_480	Lymphocyte count	2.000000e-10
GCST90002388_481	Lymphocyte count	6.000000e-24
GCST90002389_216	Lymphocyte percentage of white cells	7.000000e-15
GCST90002389_217	Lymphocyte percentage of white cells	2.000000e-10
GCST90002393_508	Monocyte count	4.000000e-11
GCST90002399_277	Neutrophil percentage of white cells	7.000000e-11
GCST90002399_278	Neutrophil percentage of white cells	2.000000e-12
GCST90002407_567	White blood cell count	2.000000e-10
GCST90002407_568	White blood cell count	6.000000e-12

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004278	sudden cardiac arrest
EFO:0004462	PR interval
EFO:0008343	sex interaction measurement
EFO:0007924	tonsillectomy risk measurement
EFO:0004587	lymphocyte count
EFO:0010125	viral load
EFO:0007969	cognitive inhibition measurement
EFO:0004531	urate measurement
EFO:0005090	basophil count
EFO:0004842	eosinophil count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0005091	monocyte count
EFO:0007990	neutrophil percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, affects methylation, decreases expression	3
Arsenic	affects methylation, increases abundance, increases expression, affects cotreatment	3
Benzo(a)pyrene	affects methylation, increases mutagenesis	3
entinostat	increases expression, affects cotreatment	2
Cisplatin	affects cotreatment, decreases expression	2
Particulate Matter	affects cotreatment, increases abundance, increases expression, increases methylation	2
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
sodium arsenate	increases abundance, increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
benzo(e)pyrene	decreases methylation, increases methylation	1
N-acetyl-4-benzoquinoneimine	affects response to substance	1
aflatoxin B2	affects methylation	1
coumarin	increases phosphorylation	1
beta-methylcholine	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Vorinostat	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Caffeine	increases phosphorylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.